Wassim Abida, MD, PhD, discusses data from the phase 3 , PROfound trial in patients with metastatic castration-resistant prostate cancer.
Wassim Abida, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses data from the phase 3, PROfound trial (NCT02987543) in patients with metastatic castration-resistant prostate cancer (mCRPC).
The PROfound study compared olaparib (Lynparza) with standard of care androgen receptor–directed therapy in men with mCRPC who had progressed on hormonal therapies, such as enzalutamide (Xtandi) or abiraterone acetate (Zytiga). Moreover, the patient population enrolled on the trial was varied because the inclusion criteria for PROfound did not require a prior line of taxane, Abida explains.
The primary end point of the study was progression-free survival. Additionally, enrollment was not limited to patients with BRCA1/2 mutations, Abida says. Instead, eligible patients had to harbor a BRCA1, BRCA2, or ATM mutation to be included in cohort A or an alternation in any of 12 other prespecified genes to be included in cohort B, Abida concludes.